No Data
No Data
No Data
No Data
No Data
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersPulmonx (NASDAQ:LUNG) shares rose 29.5% to $10.0 during Wednesday's after-market session. The market value of their outstanding shares is at $388.1 million. The company's, Q1 earnings came out
BenzingaMay 2 04:31
Compass Therapeutics' CTX-009 Gains FDA Fast Track Status
TipRanksApr 25 20:12
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
BenzingaApr 25 20:06
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study Top-line data
GlobeNewswireApr 25 20:00
HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Compass Therapeutics with a Buy and maintains $10 price target.
Analyst UpgradesApr 17 00:20
HC Wainwright & Co. : The Compass Therapeutics (CMPX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The Compass Therapeutics (CMPX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Zhitong FinanceApr 17 00:20
No Data
No Data